Advertisement
Research Article

Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness

  • Els Torreele mail,

    e.torreele@gmail.com

    Affiliation: Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland

    X
  • Bernadette Bourdin Trunz,

    Affiliation: Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland

    X
  • David Tweats,

    Affiliations: Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland, The Medical School, University of Swansea, Swansea, United Kingdom

    X
  • Marcel Kaiser,

    Affiliations: Parasite Chemotherapy, Swiss Tropical and Public Health Institute, Basel, Switzerland, University of Basel, Basel, Switzerland

    X
  • Reto Brun,

    Affiliations: Parasite Chemotherapy, Swiss Tropical and Public Health Institute, Basel, Switzerland, University of Basel, Basel, Switzerland

    X
  • Guy Mazué,

    Affiliation: Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland

    X
  • Michael A. Bray,

    Affiliation: Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland

    X
  • Bernard Pécoul

    Affiliation: Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland

    X
  • Published: December 21, 2010
  • DOI: 10.1371/journal.pntd.0000923
  • Featured in PLOS Collections

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.